Abstract
References
- Smith DH, Thorp ML, Gurwitz JH, McManus DD, Goldberg RJ, Allen LA, Hsu G, Sung SH, Magid DJ, Go AS. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study. Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):333-42. doi: 10.1161/CIRCOUTCOMES.113.000221.
- Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol. 2021 Feb 10;83:503- 28. doi: 10.1146/annurev-physiol-031620-095920.
- Kiuchi S, Hisatake S, Kabuki T, Fujii T, Oka T, Dobashi S, Hashimoto H, Ikeda T. Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report. Drug Discov Ther. 2018 Mar 19;12(1):51-4. doi: 10.5582/ddt.2017.01069.
- McMurray J. EMPA-REG - the “diuretic hypothesis”. J Diabetes Complications. 2016 Jan-Feb;30(1):3-4. doi: 10.1016/j. jdiacomp.2015.10.012.
- Mordi NA, Mordi IR, Singh JS, Baig F, Choy AM, McCrimmon RJ, Struthers AD, Lang CC. Renal and cardiovascular effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop diuretics in diabetic patients with chronic heart failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. BMJ Open. 2017 Oct 16;7(10):e018097. doi: 10.1136/bmjopen-2017-018097.
Use of SGLT-2 Inhibitor in Decompensated Heart Failure Presenting with Bilateral Resistant Pleural Effusion
Abstract
Chronic diseases concomitantly decrease quality of life and lifespan expectancy. Novel medications, including Sodium-glucose-co-transporter-2 inhibitors (SGLT-2i), affect both diabetes, heart failure, and diabetic kidney disease. These multisystemic effects give patients with mono systemic and multisystemic diseases new treatment options. Recent studies have shown that SGLT2i may benefit heart failure patients without diabetes.
In this case report, we presented a 65-years old patient who was admitted to the emergency room with shortness of breath. Bilateral pleural effusion was observed in the chest X-ray. After etiological studies, empagliflozin was initiated for pleural effusion, which is thought to be related to heart failure. The patient’s symptoms declined on the fourth day of the treatment, and the control lung X-ray revealed that the effusions declined.
References
- Smith DH, Thorp ML, Gurwitz JH, McManus DD, Goldberg RJ, Allen LA, Hsu G, Sung SH, Magid DJ, Go AS. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study. Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):333-42. doi: 10.1161/CIRCOUTCOMES.113.000221.
- Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol. 2021 Feb 10;83:503- 28. doi: 10.1146/annurev-physiol-031620-095920.
- Kiuchi S, Hisatake S, Kabuki T, Fujii T, Oka T, Dobashi S, Hashimoto H, Ikeda T. Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report. Drug Discov Ther. 2018 Mar 19;12(1):51-4. doi: 10.5582/ddt.2017.01069.
- McMurray J. EMPA-REG - the “diuretic hypothesis”. J Diabetes Complications. 2016 Jan-Feb;30(1):3-4. doi: 10.1016/j. jdiacomp.2015.10.012.
- Mordi NA, Mordi IR, Singh JS, Baig F, Choy AM, McCrimmon RJ, Struthers AD, Lang CC. Renal and cardiovascular effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop diuretics in diabetic patients with chronic heart failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. BMJ Open. 2017 Oct 16;7(10):e018097. doi: 10.1136/bmjopen-2017-018097.
Details
| Primary Language | English |
|---|---|
| Subjects | Internal Diseases |
| Journal Section | Case Reports |
| Authors | |
| Publication Date | April 1, 2022 |
| Submission Date | February 24, 2022 |
| Acceptance Date | March 9, 2022 |
| Published in Issue | Year 2022 Volume: 4 - Supplement 1 |
